The use of continuous glucose monitoring (CGM) in individuals with T1DM under continuous subcutaneous insulin infusion (CSII) therapy revealed that the control of postprandial glycemic excursions is still not achieved even after the transition from regular to rapid-acting insulin (RAI) analogs in CSII systems, creating the need for insulins with action profiles more similar to that of endogenous insulin [3]. This evidence concerns the gene INS and type 1 diabetes mellitus.